EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. Says Co Has Some ‘Big Data’ Coming Out In The Next Couple Of Months From The Co’s Clinical Trials
https://www.youtube.com/watch?v=Hcbd4bl-BLI
EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. Says Co Is Looking Into Fundraising In The Near Future
https://www.youtube.com/watch?v=Hcbd4bl-BLI
EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. Says Co’s Next Step Is To Look At A Longer Study ‘Cognitive Behavioral Effects’
https://www.youtube.com/watch?v=Hcbd4bl-BLI
Hoth Therapeutics Announces Submission Of Orphan Drug Designation Request For HT-KIT To Treat Mastocytosis
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration (FDA) for
EXCLUSIVE: Hoth Therapeutics Gives Cannabinoid-Based Lupus Candidate Back To Zylö
Hoth Therapeutics Inc (NASDAQ: HOTH) has agreed to license its cannabinoid therapeutic, HT-005, for lupus patients back to Zylö Therapeutics.
EXCLUSIVE: Hoth Therapeutics Starts Dosing In Second Cohort Of Atopic Dermatitis Trial With BioLexa
Hoth Therapeutics Inc (NASDAQ: HOTH) has begun enrollment and dosing for the second cohort in its Phase 1b trial of topical BioLexa to treat mild to moderate atopic dermatitis, also known as eczema.
EXCLSUIVE: Hoth Therapeutics Says Enrollment And Dosing Has Begun For Second Cohort In First In-Human Clinical Trial Investigating Topical BioLexa For The Treatment Of Mild-To-Moderate Atomic Dermatitis
NEW YORK, NY November 30, 2021/ PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ:
HOTH), a clinical-stage biopharmaceutical company focused on developing new generation
therapies for unmet medical needs, is pleased to